RxSight (RXST) Scheduled to Post Earnings on Monday

RxSight (NASDAQ:RXST) is scheduled to release its earnings data after the market closes on Monday, August 5th. Analysts expect RxSight to post earnings of ($0.07) per share for the quarter. RxSight has set its FY 2024 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

RxSight (NASDAQ:RXST) last announced its quarterly earnings results on Monday, May 6th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.08). The firm had revenue of $29.51 million during the quarter, compared to analysts’ expectations of $27.56 million. RxSight had a negative net margin of 44.01% and a negative return on equity of 27.68%. The company’s quarterly revenue was up 68.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.42) EPS. On average, analysts expect RxSight to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RxSight Stock Down 5.9 %

NASDAQ:RXST opened at $41.77 on Friday. RxSight has a 52-week low of $20.66 and a 52-week high of $66.54. The stock has a fifty day simple moving average of $53.84 and a 200-day simple moving average of $53.42. The company has a market capitalization of $1.55 billion, a PE ratio of -33.15 and a beta of 1.19.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on RXST. Stifel Nicolaus reduced their price target on shares of RxSight from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th. Needham & Company LLC increased their target price on RxSight from $64.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. BTIG Research raised their price target on RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Wells Fargo & Company upped their price objective on RxSight from $61.00 to $68.00 and gave the company an “overweight” rating in a research report on Tuesday, May 7th. Finally, Oppenheimer lifted their price objective on RxSight from $61.00 to $72.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 7th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $65.14.

Insider Activity

In other RxSight news, CFO Shelley B. Thunen sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $58.61, for a total value of $586,100.00. Following the sale, the chief financial officer now directly owns 13,938 shares of the company’s stock, valued at approximately $816,906.18. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Julie Andrews sold 15,625 shares of the company’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $58.00, for a total transaction of $906,250.00. Following the completion of the sale, the director now directly owns 30,287 shares in the company, valued at approximately $1,756,646. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Shelley B. Thunen sold 10,000 shares of RxSight stock in a transaction on Monday, July 1st. The shares were sold at an average price of $58.61, for a total value of $586,100.00. Following the completion of the transaction, the chief financial officer now owns 13,938 shares in the company, valued at approximately $816,906.18. The disclosure for this sale can be found here. Company insiders own 9.36% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.